|
[1]
|
JANKNEGT R. Liposomal formulations of cytotoxic drugs[J]. Support Care Cancer��1996��4��4��:298-304.
|
|
[2]
|
KHAZAELI M B��CONRY R M��LOBUGLIO A F. Human immune response to monoclonal antibodies[J]. J Immunother Emphasis Tumor Immunol��1994��15��1����42-52.
|
|
[3]
|
COUNSELL R E��POHLAND R C. Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents[J]. J Med Chem��1982��25��10����1115-1120.
|
|
[4]
|
NIKANJAM M��GIBBS A R��HUNT C A��et al. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme[J]. J Controlled Release��2007��124��3����163-171.
|
|
[5]
|
MASQUELIER M��VITOLS S��P?LSSON M��et al. Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy�� study of stability of drug-carrier complexes in blood[J]. J Drug Target��2000��8��3����155-164.
|
|
[6]
|
KADER A��PATER A. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells[J]. J Controlled Release��2002��80��1-3����29-44.
|
|
[7]
|
BIJSTERBOSCH M K��SCHOUTEN D��VAN BERKEL T J. Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles[J]. Biochemistry��1994��33��47����14073-14080.
|
|
[8]
|
YAN Y J��LI Y��LOU B��et al. Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice[J]. Life Sci��2006��79��2����210-215.
|
|
[9]
|
MCDONALD M C��DHADLY P��COCKERILL G W��et al. Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock[J]. Shock��2003��20��6����551-557.
|
|
[10]
|
NICHOLLS S J��CUTRI B��WORTHLEY S G��et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits[J]. Arterioscler Thromb Vasc Biol��2005��25��11����2416-2421.
|
|
[11]
|
NICHOLLS S J��TUZCU E M��SIPAHI I��et al. Relationship Between Atheroma Regression and Change in Lumen Size After Infusion of Apolipoprotein A-I Milano[J] J Am Coll Cardiol��2006��47��5����992�C997.
|
|
[12]
|
WASAN K M��BROCKS D R��LEE S D��et al. Impact of lipoproteins
|
|
[13]
|
on the biological activity and disposition of hydrophobic drugs��implications for drug discovery[J]. Nat Rev Drug Discov��2008��7��1����84-99.
|
|
[14]
|
HAUSENLOY D J��YELLON D M. Targeting residual cardiovascular risk��raising high-density lipoprotein cholesterol levels[J]. Heart��2008��94��6����706-714.
|
|
[15]
|
FAZIO S��LINTON M F. Apolipoprotein AI as therapy for atherosclerosis�� does the future of preventive cardiology include weekly injections of the HDL protein?[J]. Mol Interv��2003��3��8����436-440.
|
|
[16]
|
RENSEN P C��DE VRUEH R L��KUIPER J��et al. Recombinant lipoproteins�� lipoprotein-like lipid particles for drug targeting[J]. Adv Drug Deliv Rev��2001��47��2-3����251-276.
|
|
[17]
|
PATERN�� R��RUOCCO A��POSTIGLIONE A��et al. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke[J]. Cerebrovasc Dis��2004��17��2-3����204-211.
|
|
[18]
|
HAMIDI M��FOROOZESH M��ZARRIN A. Lipoproteins�� from physiological roles to drug delivery potentials[J]. Crit Rev Ther Drug Carrier Syst��2006��23��6����497-523.
|
|
[19]
|
LACKO A G��NAIR M��PARANJAPE S��et al. High density lipoprotein complexes as delivery vehicles for anticancer drugs[J]. Anticancer Res��2002��22��4����2045-2049.
|
|
[20]
|
MCCONATHY W J��NAIR M P��PARANJAPE S��et al. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel[J]. Anti Cancer Drugs��2008��19��2����183-188.
|
|
[21]
|
LOU B��LIAO X L��WU M P��et al. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells[J]. World J Gastroenterol��2005��11��7����954-959.
|
|
[22]
|
FENG M��CAI Q��HUANG H��et al. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex[J]. Eur J Pharm Biopharm��2008��68��3����688-693.
|
|
[23]
|
FENG M��CAI Q��SHI X��et al. Recombinant high-density lipoprotein complex as a targeting system of nosiheptide to liver cells[J]. J Drug Target��2008��16��6����502-508.
|
|
[24]
|
ODA M N��HARGREAVES P L��BECKSTEAD J A��et al. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B[J]. J Lipid Res��2006��47��2����260-267.
|
|
[25]
|
FRIAS J C��MA Y��WILLIAMS K J��et al. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging[J]. Nano Lett��2006��6��10����2220-2224.
|
|
[26]
|
FRIAS J C��WILLIAMS K J��FISHER E A��et al. Recombinant HDL-like nanoparticles�� a specific contrast agent for MRI of atherosclerotic plaques[J]. J Am Chem Soc��2004��126��50����16316-16317.
|
|
[27]
|
SCHERR M��BATTMER K��DALLMANN I��et al. Inhibition of GM-CSF receptor function by stable RNA interference in a NOD/SCID mouse hematopoietic stem cell transplantation model[J]. Oligonucleotides��2003��13��5����353-363.
|
|
[28]
|
SONG E��LEE S K��WANG J��et al. RNA interference targeting Fas protects mice from fulminant hepatitis[J]. Nat Med��2003��9��3����347-351.
|
|
[29]
|
WOLFRUM C��SHI S��JAYAPRAKASH K N��et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs[J]. Nat Biotechnol��2007��25��10����1149-1157.
|
|
[30]
|
KIM S I��SHIN D��CHOI T H��et al. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I[J]. Mol Ther��2007��15��6����1145-1152.
|
|
[31]
|
BIJSTERBOSCH M K��VAN BERKEL T J. Lactosylated high density lipoprotein�� a potential carrier for the site-specific delivery of drugs to parenchymal liver cells[J]. Mol Pharmacol��1992��41��2����404-411.
|
2009, Vol. 44 
